Gainplan’s iShares Biotechnology ETF IBB Stock Holding History

Gainplan’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,381	Closed	-$211K	–	57
2021 Q4	$211K	Sell	1,381 -1,272	-48%	-$197K	0.09%	54
2021 Q3	$419K	Sell	2,653 -913	-26%	-$154K	0.18%	32
2021 Q2	$563K	Buy	3,566 +1,542	+76%	+$238K	0.22%	40
2021 Q1	$305K	Buy	+2,024	New	+$321K	0.14%	56

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Gainplan's IBB Position: Q1 2022 in Review

Gainplan sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 1,381 shares — an estimated $211K sold.

Gainplan first reported a position in IBB in Q1 2021 and held it in 4 quarters. The position peaked at $563K in Q2 2021. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

Gainplan reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Gainplan sold 1,381 iShares Biotechnology ETF shares in Q1 2022, an estimated $211K.
Gainplan first reported a position in iShares Biotechnology ETF in Q1 2021 and held it in 4 quarters.
Gainplan's iShares Biotechnology ETF position peaked at $563K in Q2 2021.
897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Gainplan's 13F filing for Q1 2022, filed 10 May 2022.